NASDAQ:COGT

Cogent Biosciences Stock News

Healthcare > Biotechnology

Buy COGT

*Your capital is at risk

$32.26

-0.500 (-1.53%)

At Close: Jun 03, 2026

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

08:00am, Monday, 16'th Mar 2026

WALTHAM, Mass. and BOULDER, Colo.

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned

08:58am, Friday, 13'th Mar 2026

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish

02:05pm, Wednesday, 04'th Mar 2026

Cogent Biosciences, Inc. remains a Buy as bezuclastinib advances toward triple approval in GIST and systemic mastocytosis (advanced, non advanced). Bezuclastinib demonstrated strong efficacy in pivota

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

09:45am, Saturday, 28'th Feb 2026

WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of “Moderate Buy” from Analysts

02:27am, Wednesday, 18'th Feb 2026

Cogent Biosciences, Inc. (NASDAQ: COGT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. O

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million

03:28pm, Tuesday, 17'th Feb 2026

Rock Springs Capital Management sold 159,278 shares of Cogent Biosciences in the fourth quarter; the estimated trade size was $4.48 million based on quarterly average prices. Meanwhile, the quarter-en

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough

12:38pm, Tuesday, 17'th Feb 2026

First Turn Management acquired 824,283 shares of Cogent Biosciences in the fourth quarter. The quarter-end value for the new stake rose by $29.28 million, reflecting both trading activity and price mo

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

08:00am, Tuesday, 17'th Feb 2026

SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 PEAK NDA initiated for bezuclastini

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

08:00am, Tuesday, 10'th Feb 2026

WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define

Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M

01:39am, Sunday, 01'st Feb 2026

Fairmount Funds Management LLC sold 3,500,000 shares indirectly on Jan. 22, 2026, at $36.40 per share, generating a transaction value of approximately $127.4 million. This sale represented 38.87% of t

Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag

10:06am, Monday, 26'th Jan 2026

The FDA granted breakthrough status to Cogent's GIST drug combo after a trial showed it cut disease progression or death risk by 50% compared with current treatment.

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

08:00am, Monday, 26'th Jan 2026

- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by